A ‘pre‐induction course’ with non‐cross‐reacting cytostatic drugs for rapid tumour load reduction improves outcome in adult acute lymphoblastic leukaemia

Saved in:
Bibliographic Details
Published inBritish journal of haematology Vol. 138; no. 2; pp. 275 - 277
Main Authors Daenen, Simon, Van Imhoff, Gustaaf W., De Wolf, Joost T.M., Vellenga, Edo, Van Den Berg‐de Ruiter, Eva, Kluin‐Nelemans, Hanneke C.
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Publishing Ltd 01.07.2007
Blackwell
Subjects
acute lymphoblastic leukaemia
Adolescent
Adult
Aged
allogeneic stem cell transplantation
Antineoplastic Agents - therapeutic use
Biological and medical sciences
chemotherapy
Cytarabine - therapeutic use
Drug Therapy, Combination
Etoposide - therapeutic use
Female
Hematologic and hematopoietic diseases
Humans
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Male
Medical sciences
Methotrexate - therapeutic use
Middle Aged
Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
survival
toxicity
Treatment Outcome
Tumor Burden - drug effects
Human
Drug
Load
Prognosis
Hematology
Cytostatic
Acute leukemia
Malignant hemopathy
Lymphoid neoplasm
Lymphoproliferative syndrome
Cross reaction
Adult
Tumor
Acute lymphocytic leukemia
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ISSN:0007-1048
1365-2141
DOI:10.1111/j.1365-2141.2007.06645.x